Summary
Vertex Pharmaceuticals Inc. (VRTX) announced an amendment and expansion of its Research, Development, and Commercialization Agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (CFFT) on October 13, 2016. This amendment is significant for investors as it clarifies the ongoing collaboration and includes substantial financial terms. The agreement introduces an upfront program award of $75.0 million from CFFT to Vertex, along with annual development funding of up to $6.0 million. These funds are expected to support Vertex's continued research and development efforts in cystic fibrosis (CF). Furthermore, the amendment addresses royalty payments on certain compounds. Vertex will pay royalties ranging from low to mid-single digits on compounds synthesized and/or tested between March 1, 2014, and August 31, 2016. Existing royalty structures for earlier compounds remain in place. The company also entered into a separate data license agreement to maintain access to the CFF's patient registry data, crucial for future CF medicine development. This updated collaboration framework provides clarity and reinforces Vertex's strategic partnership with CFFT.
Key Highlights
- 1Vertex Pharmaceuticals amended and expanded its Research, Development, and Commercialization Agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (CFFT).
- 2The amendment includes an upfront program award of $75.0 million from CFFT to Vertex.
- 3Vertex will receive annual development funding of up to $6.0 million from CFFT.
- 4New royalty terms are established for compounds synthesized/tested between March 1, 2014, and August 31, 2016, ranging from low to mid-single digits.
- 5Existing royalty structures for earlier compounds remain unchanged.
- 6The agreement clarifies the calculation of royalties on combination products, allocating net sales equally.
- 7Vertex entered into a separate data license agreement for continued access to the CFF's patient registry data.